Stimuli-responsive nanocarriers have attracted increased attention as materials that can facilitate
drug and gene delivery in
cancer therapy. The present study reports the development of redox-sensitive dendrimersomes comprising
disulfide-linked
cholesterol-bearing PEGylated
dendrimers, which can be used as
drug and gene delivery systems. Two
disulfide-linked
cholesterol-bearing PEGylated generation 3 diaminobutyric
polypropylenimine dendrimers have been successfully synthesized via an in situ two-step reaction. They were able to spontaneously self-assemble into stable, cationic, nanosized vesicles (or dendrimersomes) with lower critical aggregation concentration values for high-
cholesterol-bearing vesicles. These dendrimersomes were able to entrap both hydrophilic and hydrophobic
dyes, and they also showed a redox-responsive sustained release of the entrapped guests in the presence of a
glutathione concentration similar to that of a cytosolic reducing environment. The high-
cholesterol-bearing dendrimersomes were found to have a higher melting enthalpy, increased adsorption tendency on
mica surface, entrapping ability for a larger amount of hydrophobic drugs, and increased resistance to redox-responsive environments in comparison with their low-
cholesterol counterpart. In addition, both dendrimersomes were able to condense more than 85% of the
DNA at all the tested ratios for the low-
cholesterol vesicles, and at dendrimer : DNA weight ratios of 1 : 1 and higher for the high-
cholesterol vesicles. These vesicles resulted in an enhanced cellular uptake of
DNA, by up to 15-fold when compared with naked
DNA with low-
cholesterol vesicles. As a result, they increased the gene transfection on the PC-3
prostate cancer cell line, with the highest transfection being obtained with low-
cholesterol vesicle complexes at a dendrimer : DNA weight ratio of 5 : 1 and high-
cholesterol vesicle complexes at a dendrimer : DNA weight ratio of 10 : 1. These transfection levels were about 5-fold higher than those observed when treated with naked
DNA. These
cholesterol-bearing PEGylated
dendrimer-based vesicles are, therefore, promising as redox-sensitive drugs and gene delivery systems for potential applications in combination
cancer therapies.